Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 11/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 11/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22207235 | 1.00 | AKT1 (0.45) | AKT1TDP1ATMNPSR1KMT2A | |
| SCHEMBL23113662 | 0.91 | AKT1 (0.48) | AKT1KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL28620433 | 0.88 | AKT1 (0.61) | AKT1TDP1NPSR1KMT2AMEN1 | |
| SCHEMBL31374732 | 0.88 | AKT1 (0.61) | AKT1TDP1NPSR1KMT2AMEN1 | |
| SCHEMBL28625037 | 0.86 | CTSS (0.48) | AKT1POLBMAPTKDM4EALDH1A1 | |
| SCHEMBL28620369 | 0.85 | AKT1 (0.41) | AKT1TDP1ATMNPSR1KMT2A | |
| SCHEMBL28624848 | 0.85 | AKT1 (0.41) | AKT1TDP1ATMNPSR1KMT2A | |
| SCHEMBL31441165 | 0.85 | AKT1 (0.44) | AKT1TDP1ATMNPSR1KMT2A | |
| SCHEMBL28620704 | 0.85 | AKT1 (0.44) | AKT1TDP1ATMNPSR1KMT2A | |
| SCHEMBL31374701 | 0.83 | AKT1 (0.37) | AKT1TDP1ATMNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202908-B2 | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand | ASTELLAS PHARMA INC. (JP) | 2025-01-21 | — | — | US | disclosed |
| WO-2020145228-A1 | COMPLEX COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
| WO-2020145227-A1 | COMPLEX COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE | アステラス製薬株式会社 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202908-B2 | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand | MUC1, SIGLEC7, CA14 | AKT1 4874/4885TDP1 4403/4885ATM 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.